2020
Perceptions of patients with early stage breast cancer toward research biopsies
Seah DS, Leone JP, Openshaw TH, Scott SM, Tayob N, Hu J, Lederman RI, Frank ES, Sohl JJ, Stadler ZK, Erick TK, Silverman SG, Peppercorn JM, Winer EP, Come SE, Lin NU. Perceptions of patients with early stage breast cancer toward research biopsies. Cancer 2020, 127: 1208-1219. PMID: 33320362, PMCID: PMC8247276, DOI: 10.1002/cncr.33371.Peer-Reviewed Original ResearchMeSH KeywordsAcademies and InstitutesAdultAgedAged, 80 and overAnalysis of VarianceAttitudeBiomedical ResearchBiopsyBlood DonorsBreastBreast NeoplasmsCancer Care FacilitiesFemaleHealth Services AccessibilityHumansMiddle AgedNeoplasm StagingSocioeconomic FactorsSurveys and QuestionnairesTissue and Organ ProcurementTissue DonorsConceptsEarly-stage breast cancerEarly breast cancerStage breast cancerResearch biopsiesBreast cancerMore patientsClinical trialsBreast biopsyMultivariate analysisProportion of patientsAcademic sitesCommunity oncology practicesPerceptions of patientsPerspectives of patientsCommunity-based sitesCommunity sitesMost patientsOncology sitesModifiable factorsPatients' willingnessUnivariate analysisOncology practiceBiopsyPatientsAcademic centers
2019
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.
Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, Crowley L, Kuhnly N, Files J, Lindeman NI, MacConaill LE, Kumari P, Tolaney SM, Krop IE, Bose R, Johnson BE, Ma CX, Dillon DA, Winer EP, Wagle N, Lin NU. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precision Oncology 2019, 3: 1-9. PMID: 32923853, PMCID: PMC7446367, DOI: 10.1200/po.19.00087.Peer-Reviewed Original ResearchMetastatic breast cancerEligible patientsBreast cancerExact testHER2-negative breast cancerOngoing phase II trialGenomic profilingPhase II trialProportion of patientsComprehensive genomic profilingRoutine clinical practiceFisher's exact testGenomic tumor profilingArchived tissue samplesII trialMedian timeTRIAL REGISTRATIONTrial participationClinical trialsSpecific genomic changesClinical impactGenomic testing resultsRare subsetPatientsClinical practice
2017
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). The AAPS Journal 2017, 19: 1411-1423. PMID: 28620884, PMCID: PMC5711539, DOI: 10.1208/s12248-017-0101-9.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyProportion of patientsMetastatic breast cancerKinetic-pharmacodynamic modelIndirect response modelNab-paclitaxelDose modificationPeripheral neuropathyBreast cancerDrug effectsRandomized phase III trialLinear drug effectFirst-line chemotherapyPhase III trialsTime pointsDose-limiting toxicityLater time pointsEarly time pointsCALGB 40502Neurotoxicity ScaleIII trialsFunctional assessmentChemotherapeutic agentsPatientsCancerFactors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population‐Based Study
Vaz‐Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA. Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population‐Based Study. The Oncologist 2017, 22: 386-393. PMID: 28242790, PMCID: PMC5388378, DOI: 10.1634/theoncologist.2016-0369.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerMonths of diagnosisQuarter of patientsEarly deathBreast cancerPoor outcomeUninsured statusHigh riskDe novo metastatic breast cancerEarly palliative care referralNovo metastatic breast cancerHuman epidermal growth factor receptor 2Older ageEpidermal growth factor receptor 2Palliative care referralHalf of patientsProportion of patientsEnd Results (SEER) dataGrowth factor receptor 2Identification of patientsClinical trial participationFactor receptor 2Additional supportive servicesProportion of womenEquitable patient access
2016
Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers
Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Research And Treatment 2016, 155: 569-578. PMID: 26868124, DOI: 10.1007/s10549-016-3707-1.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryUse of mastectomyBreast cancer patientsInitial mastectomyBilateral mastectomyBreast cancerDefinitive surgeryInitial surgeryCancer patientsNational Comprehensive Cancer Network centersSmall node-negative breast cancersStage I breast cancer patientsNode-negative breast cancerStage I breast cancerRisk breast cancerSubstantial institutional variationProportion of patientsProspective cohort studyUS academic centersI breast cancerType of surgeryLonger median timeChoice of surgeryEquivalent survival outcomesSignificant institutional variation
2013
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
Lin NU, Seah DS, Gelman R, Desantis S, Mayer EL, Isakoff S, DiPiro P, Krop IE, Come SE, Weckstein D, Winer EP, Burstein HJ. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Research And Treatment 2013, 139: 403-410. PMID: 23645007, DOI: 10.1007/s10549-013-2551-9.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerGrade 3/4 non-hematologic toxicitiesHER2-positive metastatic breast cancerNon-hematologic toxicitiesTreatment-related toxicityBreast cancerCommon treatment-related toxicitiesFirst-line patientsProtocol-based therapySecond-line cohortSecond-line patientsSecond-line settingPhase II studyProportion of patientsCombination of vinorelbineCo-primary endpointsEligible patientsFebrile neutropeniaMedian PFSII studyMedian durationObjective responsePrior linesUnacceptable toxicityMedian age
2007
Brain Metastases: The HER2 Paradigm
Lin NU, Winer EP. Brain Metastases: The HER2 Paradigm. Clinical Cancer Research 2007, 13: 1648-1655. PMID: 17363517, DOI: 10.1158/1078-0432.ccr-06-2478.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerCNS diseaseBreast cancerCentral nervous system metastasesExtra-CNS diseaseImportant sanctuary siteNervous system metastasesProportion of patientsTerms of prognosisCNS metastasesCNS progressionBrain metastasesCytotoxic chemotherapySystemic therapyAdvanced cancerTherapeutic challengePrimary diagnosisHistorical controlsTargeted therapyPreventive strategiesSanctuary siteTumor subtypesParticular tumor subtypesPatientsNatural history
2004
CNS metastases in breast cancer.
Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. Journal Of Clinical Oncology 2004, 22: 3608-17. PMID: 15337811, DOI: 10.1200/jco.2004.01.175.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyBreast cancerCNS metastasesStereotactic radiosurgeryProportion of patientsMetastatic breast cancerGroup of patientsSingle brain metastasisBrain metastasesCNS involvementMultiple metastasesNeurologic symptomsSystemic therapyMedical therapyAppropriate therapyCase seriesClinical presentationRandomized trialsRetrospective seriesCase reportSolid tumorsMetastasisPatientsCancerRoutine use